# Study of LY2157299 in Japanese Participants With Cancer

> **NCT01722825** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 12 (estimated)

## Conditions studied

- Neoplasms
- Neoplasm Metastasis

## Interventions

- **DRUG:** LY2157299

## Key facts

- **NCT ID:** NCT01722825
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2014-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01722825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01722825, "Study of LY2157299 in Japanese Participants With Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01722825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*